The Intussusception Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Intussusception Market:
https://www.thebusinessresearchcompany.com/report/intussusception-global-market-report

According to The Business Research Company’s Intussusception Global Market Report 2024, The intussusception market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.45 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to improved diagnostic capabilities, increased awareness and education, global healthcare infrastructure growth, research and development investments, collaboration among healthcare entities..

The intussusception market size is expected to see steady growth in the next few years. It will grow to $5.3 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to continued medical education initiatives, pediatric vaccination programs, global efforts in pediatric healthcare, focus on postoperative care, rising demand for pediatric gastrointestinal research, telemedicine and remote healthcare access.. Major trends in the forecast period include advancements in diagnostic imaging, minimally invasive treatment approaches, development of pediatric-specific interventions, research on etiology and risk factors, global epidemiological studies, implementation of vaccination programs, telemedicine for diagnosis and consultation..

The rising incidence of intestinal disorders is expected to propel the growth of the intussusception market going forward. An intestinal disorder refers to any medical condition or health issue that affects the normal functioning of the intestines, which are parts of the digestive system responsible for absorbing nutrients and eliminating waste from the body. An increasing incidence of intestinal disorders such as inflammatory bowel disease and gastrointestinal cancers can lead to earlier diagnosis, improved treatment options, and enhanced support for intussusception patients, ultimately benefiting their health and well-being. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, gastrointestinal cancers increased by 3.18% to 348,840 compared to 338,090 in 2021 in the United States. Therefore, the rising incidence of intestinal disorders will drive the growth of the intussusception market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13466&type=smp

The intussusception market covered in this report is segmented –
1) Intussusception Market By Type: Idiopathic Intussusception, Secondary Intussusception
2) Intussusception Market By Treatment: Enema Reduction, Surgery, Other Treatment
3) Intussusception Market By Diagnosis: Barium Enema, Ultrasound, X-Ray, Computerized Tomography (CT)
4) Intussusception Market By End-User: Hospitals, Clinics, Other End-User

Major companies operating in the intestinal pseudo-obstruction treatment market are developing novel drug therapies, such as NHE3 inhibitor treatment therapy, to provide reliable services to customers. NHE3 inhibitor treatment therapy is a medication that works by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, introduced IBSRELA, an NHE3 inhibitor treatment for irritable bowel syndrome with constipation (IBS-C) in adults, potentially improving gastrointestinal motility. IBSRELA treatment therapy works by inhibiting or blocking the activity of the Sodium-Hydrogen Exchanger 3 (NHE3) protein. IBSRELA's approval was based on two Phase 3 trials with over 1,200 IBS-C patients, where it significantly improved abdominal pain and bowel movements, meeting the primary endpoint, with improvements observed as early as Week 1 and sustained for 26 weeks in the long-term trial.

The intussusception market report table of contents includes:

1. Executive Summary

2. Intussusception Market Characteristics

3. Intussusception Market Trends And Strategies

4. Intussusception Market - Macro Economic Scenario

5. Global Intussusception Market Size and Growth

.....

32. Global Intussusception Market Competitive Benchmarking

33. Global Intussusception Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Intussusception Market

35. Intussusception Market Future Outlook and Potential Analysis

36. Appendix

Read Related Reports:

https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model